Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains

J. Mukherjee, Matthew D. Scharff, A. Casadevall

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The efficacy of monoclonal antibody (MAb 2H1) against diverse strains of Cryptococcus neoformans was studied in a murine model of intravenous infection. For six of eight strains, administration of MAb prior to infection prolonged survival of mice. For two strains, 371 and SB4A, administration of MAb prior to infection did not prolong survival in multiple experiments with inocula ranging from 102 to 106 yeast cells per mouse. Mice infected with strains 371 and SB4A had fewer CFU than non-MAb-treated controls, but the CFU reduction was not sufficient to affect survival. Serum glucuronoxylomannan (GXM) levels varied for the different C. neoformans strains. For mice that did not receive MAb 2H1, there was a positive correlation between lung fungal burden and serum GXM levels. MAb 2H1-treated mice had significantly reduced serum GXM levels. The results indicate that the efficacy of MAb 2H1 administration in prolonging survival and/or reducing organ CFU varies with the C. neoformans strain.

Original languageEnglish (US)
Pages (from-to)3353-3359
Number of pages7
JournalInfection and Immunity
Volume63
Issue number9
StatePublished - 1995

Fingerprint

Cryptococcus neoformans
Antibodies
Infection
Serum
Yeasts
Monoclonal Antibodies
Lung
glucuronoxylomannan

ASJC Scopus subject areas

  • Immunology

Cite this

Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. / Mukherjee, J.; Scharff, Matthew D.; Casadevall, A.

In: Infection and Immunity, Vol. 63, No. 9, 1995, p. 3353-3359.

Research output: Contribution to journalArticle

@article{192f9fac61e248ebb4847347775fc68c,
title = "Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains",
abstract = "The efficacy of monoclonal antibody (MAb 2H1) against diverse strains of Cryptococcus neoformans was studied in a murine model of intravenous infection. For six of eight strains, administration of MAb prior to infection prolonged survival of mice. For two strains, 371 and SB4A, administration of MAb prior to infection did not prolong survival in multiple experiments with inocula ranging from 102 to 106 yeast cells per mouse. Mice infected with strains 371 and SB4A had fewer CFU than non-MAb-treated controls, but the CFU reduction was not sufficient to affect survival. Serum glucuronoxylomannan (GXM) levels varied for the different C. neoformans strains. For mice that did not receive MAb 2H1, there was a positive correlation between lung fungal burden and serum GXM levels. MAb 2H1-treated mice had significantly reduced serum GXM levels. The results indicate that the efficacy of MAb 2H1 administration in prolonging survival and/or reducing organ CFU varies with the C. neoformans strain.",
author = "J. Mukherjee and Scharff, {Matthew D.} and A. Casadevall",
year = "1995",
language = "English (US)",
volume = "63",
pages = "3353--3359",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains

AU - Mukherjee, J.

AU - Scharff, Matthew D.

AU - Casadevall, A.

PY - 1995

Y1 - 1995

N2 - The efficacy of monoclonal antibody (MAb 2H1) against diverse strains of Cryptococcus neoformans was studied in a murine model of intravenous infection. For six of eight strains, administration of MAb prior to infection prolonged survival of mice. For two strains, 371 and SB4A, administration of MAb prior to infection did not prolong survival in multiple experiments with inocula ranging from 102 to 106 yeast cells per mouse. Mice infected with strains 371 and SB4A had fewer CFU than non-MAb-treated controls, but the CFU reduction was not sufficient to affect survival. Serum glucuronoxylomannan (GXM) levels varied for the different C. neoformans strains. For mice that did not receive MAb 2H1, there was a positive correlation between lung fungal burden and serum GXM levels. MAb 2H1-treated mice had significantly reduced serum GXM levels. The results indicate that the efficacy of MAb 2H1 administration in prolonging survival and/or reducing organ CFU varies with the C. neoformans strain.

AB - The efficacy of monoclonal antibody (MAb 2H1) against diverse strains of Cryptococcus neoformans was studied in a murine model of intravenous infection. For six of eight strains, administration of MAb prior to infection prolonged survival of mice. For two strains, 371 and SB4A, administration of MAb prior to infection did not prolong survival in multiple experiments with inocula ranging from 102 to 106 yeast cells per mouse. Mice infected with strains 371 and SB4A had fewer CFU than non-MAb-treated controls, but the CFU reduction was not sufficient to affect survival. Serum glucuronoxylomannan (GXM) levels varied for the different C. neoformans strains. For mice that did not receive MAb 2H1, there was a positive correlation between lung fungal burden and serum GXM levels. MAb 2H1-treated mice had significantly reduced serum GXM levels. The results indicate that the efficacy of MAb 2H1 administration in prolonging survival and/or reducing organ CFU varies with the C. neoformans strain.

UR - http://www.scopus.com/inward/record.url?scp=0029094448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029094448&partnerID=8YFLogxK

M3 - Article

C2 - 7642262

AN - SCOPUS:0029094448

VL - 63

SP - 3353

EP - 3359

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 9

ER -